Press Release Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) Dyne Therapeutics, Inc. · Jul 28
Press Release Riot Announces Second Quarter 2026 Earnings Conference Call Riot Platforms, Inc. · Jul 28
Press Release Department of Culture and Tourism – Abu Dhabi Announces 11 December 2026 Opening of Guggenheim Abu Dhabi Department of Culture and Tourism - Abu Dhabi · Jul 28
Press Release China Literature to Report First Half 2026 Financial Results on August 11, 2026 China Literature · Jul 28
Press Release VR Confirms New IP and Conductivity Anomalies on its Bonita Property Porphyry Copper-Gold Project in Nevada VR Resources Ltd. · Jul 28
Press Release National Civil Rights Museum Hosts the 2026 Ruby Bridges Reading Festival National Civil Rights Museum · Jul 28
Press Release Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus Atea Pharmaceuticals, Inc. · Jul 28
Press Release Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients Lungpacer Medical USA Inc. · Jul 28
Press Release Midera Food Processing Schedules Second Quarter 2026 Earnings Release and Conference Call Midera Food Processing, Inc. · Jul 28
Press Release DoubleDown Interactive to Report 2026 Second Quarter Results on August 11 and Host Conference Call and Webcast DoubleDown Interactive Co., Ltd. · Jul 28
Press Release Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration Grace Therapeutics, Inc. · Jul 28
Press Release Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML Cullinan Therapeutics, Inc. · Jul 28